- Home
- CAPT vs ALLK Comparison
CAPT vs ALLK Comparison
Compare CAPT & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- ALLK
- Stock Information
- Founded
- CAPT 2005
- ALLK 2012
- Country
- CAPT South Korea
- ALLK United States
- Employees
- CAPT N/A
- ALLK N/A
- Industry
- CAPT Blank Checks
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- CAPT Finance
- ALLK Health Care
- Exchange
- CAPT Nasdaq
- ALLK Nasdaq
- Market Cap
- CAPT 57.0M
- ALLK 58.0M
- IPO Year
- CAPT N/A
- ALLK 2018
- Fundamental
- Price
- CAPT $1.63
- ALLK $0.65
- Analyst Decision
- CAPT
- ALLK Hold
- Analyst Count
- CAPT 0
- ALLK 5
- Target Price
- CAPT N/A
- ALLK $1.67
- AVG Volume (30 Days)
- CAPT 105.4K
- ALLK 302.5K
- Earning Date
- CAPT 01-01-0001
- ALLK 11-11-2024
- Dividend Yield
- CAPT N/A
- ALLK N/A
- EPS Growth
- CAPT N/A
- ALLK N/A
- EPS
- CAPT N/A
- ALLK N/A
- Revenue
- CAPT $17,389,944.00
- ALLK N/A
- Revenue This Year
- CAPT N/A
- ALLK N/A
- Revenue Next Year
- CAPT N/A
- ALLK N/A
- P/E Ratio
- CAPT N/A
- ALLK N/A
- Revenue Growth
- CAPT 84.70
- ALLK N/A
- 52 Week Low
- CAPT $1.15
- ALLK $0.54
- 52 Week High
- CAPT $12.00
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- CAPT 28.41
- ALLK 50.32
- Support Level
- CAPT $1.92
- ALLK $0.63
- Resistance Level
- CAPT $2.03
- ALLK $0.70
- Average True Range (ATR)
- CAPT 0.14
- ALLK 0.05
- MACD
- CAPT -0.05
- ALLK 0.00
- Stochastic Oscillator
- CAPT 0.00
- ALLK 33.33
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.